Vanda Pharmaceuticals | VNDA - Current Liabilities


Vanda Pharmaceuticals reported $145.16M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 596.57M 157.83M Sep/2026
J&J USD 55.46B 562M Sep/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.03B 506M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 29.77B 2.16B Sep/2026
Takeda JPY 2.6T 161B Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Veracyte USD 84.21M 21.47M Sep/2026